Targeting metalloenzymes for therapeutic intervention

AY Chen, RN Adamek, BL Dick, CV Credille… - Chemical …, 2018 - ACS Publications
Metalloenzymes are central to a wide range of essential biological activities, including
nucleic acid modification, protein degradation, and many others. The role of metalloenzymes …

The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases

VK Raker, C Becker, K Steinbrink - Frontiers in immunology, 2016 - frontiersin.org
Nucleotide signaling molecules contribute to the regulation of cellular pathways. In the
immune system, cyclic adenosine monophosphate (cAMP) is well established as a potent …

Clinical and molecular genetics of the phosphodiesterases (PDEs)

MF Azevedo, FR Faucz, E Bimpaki, A Horvath… - Endocrine …, 2014 - academic.oup.com
Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that have the unique function of
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …

Advances in the development of phosphodiesterase-4 inhibitors

T Peng, B Qi, J He, H Ke, J Shi - Journal of Medicinal Chemistry, 2020 - ACS Publications
Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine
monophosphate (cAMP) and plays vital roles in biological processes such as cancer …

Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases

M Wittmann, PS Helliwell - Dermatology and therapy, 2013 - Springer
Agents which increase intracellular cyclic adenosine monophosphate (cAMP) may have an
antagonistic effect on pro-inflammatory molecule production so that inhibitors of the cAMP …

Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases

F Omar, JE Findlay, G Carfray… - Proceedings of the …, 2019 - National Acad Sciences
Cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) enzymes degrade cAMP and underpin the
compartmentalization of cAMP signaling through their targeting to particular protein …

cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases

A Martinez, C Gil - Expert opinion on therapeutic patents, 2014 - Taylor & Francis
Introduction: PDEs are key enzymes in the adenosine and guanosine cyclic nucleotides
(cAMP and cGMP) signaling cascade. Their inhibition increases cyclic nucleotide levels …

JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease

MD Howell, C Fitzsimons, PA Smith - Annals of Allergy, Asthma & …, 2018 - Elsevier
Objective To provide an overview of janus kinase (JAK), chemoattractant receptor
homologous molecule expressed on TH 2 cells (CRTH2), and phosphodiesterase 4 (PDE4) …

PDE4 inhibition and inflammatory bowel disease: a novel therapeutic avenue

M Spadaccini, S D'Alessio, L Peyrin-Biroulet… - International Journal of …, 2017 - mdpi.com
Background. In the last few decades, a better knowledge of the inflammatory pathways
involved in the pathogenesis of Inflammatory Bowel Disease (IBD) has promoted biological …

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors

M Perez-Aso, MC Montesinos, A Mediero… - Arthritis research & …, 2015 - Springer
Introduction This work was undertaken to delineate intracellular signaling pathways for the
PDE4 inhibitor apremilast and to examine interactions between apremilast, methotrexate …